DUBLIN--(BUSINESS WIRE)--The "Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents, Software, Services), Application (Clinical, Oncology, Forensics), End-user (Hospitals, Diagnostic Labs, Academia, Pharma-Biotech, CRO) - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
The global dPCR and qPCR market is projected to reach USD 6.3 billion by 2024 from USD 4.1 billion in 2019, at a CAGR of 8.8% from 2019 to 2024.
The rising incidence of infectious diseases and genetic disorders across the world has spurred the demand for better and faster diagnostic tests. This has also boosted the overall pace of R&D in the dPCR and qPCR market along with the availability of strong financial support in the form of investments, funds, and grants. These factors are driving the growth of dPCR and qPCR market during the forecast period. However, high instrument costs - especially that of dPCR - and the technical limitations of PCR are expected to limit market growth to a certain extent.
The qPCR reagents segment is expected to account for the largest market share of the global qPCR products and services market in 2019
The qPCR reagents and consumables segment is expected to account for the largest share among qPCR products in 2019. The expansion of qPCR applications in the field of clinical diagnosis, forensics, and genomic research, along with the increased funding for life science research and the rising number of probe-based multiplex genetic analysis procedures, are responsible for the dominance of the qPCR reagents and consumables segment.
Clinical applications to show the highest growth in the dPCR and qPCR applications market during the forecast period
The clinical applications segment will show the highest growth in the dPCR and qPCR applications market during the forecast period. The growth of this segment can be attributed to factors such as the growing usage of qPCR in disease diagnosis, rising incidence of infectious and genetic diseases, and growing public emphasis on early & effective disease diagnosis & treatment. Furthermore, the technological benefits (such as high flexibility, increased device sensitivity, better precision, and absolute quantification of the target molecule) offered by dPCR over traditional disease testing techniques and the growing adoption of dPCR among hospitals & diagnostic centers are other factors driving the growth of this segment in the forecast period.
North America to account for the largest share of the global market in 2019
North America accounts for the largest share of the dPCR and qPCR market owing to the high incidence of chronic and genetic diseases, rising geriatric population, growing adoption of qPCR and dPCR techniques in research & academia, and significant public-private funding in the field of genome analysis. Further, the strong presence of major pharmaceutical and biotechnology companies in the US and ongoing initiatives by the Canadian government to support life science, genomic, and clinical research are other few factors influencing the demand of dPCR and qPCR products in this region.
- Abbott Laboratories
- Agilent Technologies, Inc.
- Analytik Jena AG (a wholly owned subsidiary of Endress+Hauser AG)
- Becton Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Biomrieux S.A.
- Danaher Corporation
- Eppendorf AG
- F. Hoffman-La Roche Ltd.
- Fluidigm Corporation
- Merck KGaA
- Promega Corporation
- Qiagen N.V.
- Takara Bio, Inc.
- Thermo Fisher Scientific, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/ic3zs9